0A5J.LSE Dermapharm Holding SE
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 1.87%
- Fundamental score
- -
Is 0A5J.LSE undervalued?
Graham numberThe Graham number of Dermapharm Holding SE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dermapharm Holding SE fundamental analysis
No fundamental analysis for Dermapharm Holding SE yet.
Dermapharm Holding SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal e…
Full company profileFinancial statements of Dermapharm Holding SE are not available yet.
Dermapharm Holding SE dividends
Dermapharm Holding SE has not paid dividends in the last 4 fiscal years.
Who owns Dermapharm Holding SE
- Insiders 89.30%
- Institutions 6.61%
- Public & others 4.09%
- Free float 6.46M
Dermapharm Holding SE company profile
- Company name
- Dermapharm Holding SE
- Ticker
- 0A5J.LSE
- ISIN
- DE000A2GS5D8
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 3,619
- Fiscal year end
- December
- Address
- Lil-Dagover-Ring 7, Grünwald, Germany, 82031
- Phone
- 49 89 6 41 86 0
- Website
- ir.dermapharm.de
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
Dermapharm Holding SE management
4- Dr. Hans-Georg FeldmeierCEO & Chairman of the Management Board
- Mr. Christof DreibholzCFO, Chief Compliance Officer & Member of Management Board · born 1968
- Dr. Andreas EberhornChief Marketing Officer & Member of Management Board · born 1976
- Ms. Britta HambergerHead of Investor Relations & Corporate Communications